Show simple item record

dc.contributor.authorMedrano, Luz Maria 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorTejerina, Francisco
dc.contributor.authorDiez, Cristina
dc.contributor.authorVigon-Hernandez, Lorena 
dc.contributor.authorFernandez-Rodriguez, Amanda 
dc.contributor.authorResino, Salvador
dc.identifier.citationSci Rep. 2017 Oct 10;7(1):12918.es_ES
dc.description.abstractThe adenosine deaminase acting on RNA (ADAR1) gene is an interferon-stimulated gene involved in liver injury protection. Our aim was to analyze the association of polymorphisms within this gene with the severity of liver disease in European HIV/HCV-coinfected patients. We performed a cross-sectional study in 220 patients that underwent a liver biopsy. Five SNPs in the ADAR1 gene (rs1127326, rs1127317, rs1127314, rs1127313, rs2229857) were genotyped by GoldenGate assay. The outcome variables were fibrosis stage and necroinflammatory activity grade by METAVIR-score, aspartate aminotransferase to platelet ratio index (APRI), FIB-4 index, and fibrosis progression rate (FPR). In multivariate analysis, fibrosis progression rate (FPR) (aAMRs = 0.97) decreased in a dose-dependent manner with the presence of rs2229857_T, rs1127313_G, rs1127314_G and rs1127317_G; while rs1127326_T allele had only significant associations with FIB-4 (aAMRs ≤ 0.63) and FPR (aAMRs ≤ 0.97). Moreover, carriers of rs2229857_T, rs1127314_G, rs1127317_G, and rs1127326_T alleles were protected against advanced fibrosis (F ≥ 3) (adjusted ORs (aORs) ≤ 0.44), APRI ≥ 1.5 (aORs ≤ 0.33), and FPR ≥ 0.075 (aORs ≤ 0.45). rs1127313_G carriers showed lower odds of having F ≥ 3 (aORs = 0.39), FIB4 ≥ 3.25 (aOR = 0.22) and FPR ≥ 0.075 (aORs = 0.44). In conclusion, ADAR1 polymorphisms protected against severe liver disease in HIV/HCV-coinfected patients. These results could be used to improve therapeutic decision-making in clinical practice.es_ES
dc.description.sponsorshipThis work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI14/01094, PI14CIII/00011] and Red Española de Investigación en SIDA (RIS) [AIDS Research Network] [grant numbers RD16CIII/0002/0002 and RD16/0025/0017]. This work has been (partially) funded by the RD16/0025 project as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). LMM, MAJS, AFR, and LV are supported by “Instituto de Salud Carlos III” [grant numbers CD14/00002, CD13/00013, CP14/0010, and PEJ15/BIO/AI-0156, respectively]. JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS).es_ES
dc.publisherNature Publishing Groupes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.titleADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patientses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderRed Española de Investigación en SIDAes_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional